There was no difference in the distribution of low, moderate and high Y-27632 molecular weight Caffeine use between the two groups (p = 0.44). Table 1 Descriptive data for AA homozygotes and
C allele carriers A/A (n = 16) C (n = 19) Height (cm) 179.1 ± 10.6 178.0 ± 7.1 Weight (kg) 74.3 ± 12.5 73.7 ± 12.2 Age 24.0 ± 6.9 26.1 ± 7.8 VO2max (L·min-1) 4.30 ± 0.45 4.31 ± 0.58 VO2max (ml·kg-1·min-1) 59.04 ± 9.29 59.61 ± 10.31 Caffeine intake (mg per day) 85.71 ± 106.49 86.62 ± 145.40 Figure 1 displays the average 40-km times for both groups. There was a significant (p < 0.001) main effect for Treatment (Caffeine < Placebo) and a significant (p = 0.005) Treatment × Genotype interaction, such that caffeine lowered average (mean ± SD) 40-km time in AA homozygotes (4.9%; caffeine = 72.4 ± 4.2 click here min, placebo = 76.1 ± 5.8 min) to a greater degree than the C allele carriers (1.8%; caffeine = 70.9 ± 4.3 min, placebo = 72.2 ± 4.2 min). Caffeine significantly decreased 40-km time in the AA homozygotes (p < 0.001), with a strong trend towards decreased 40-km time in C allele carriers (p = 0.04). Individual data for the 40-km times in both groups are displayed in Figure 2. Note
that data points above the line of identity reflect an improvement in 40-km time in the caffeine trial. Caffeine resulted in at least a 1-minute improvement in 40 k
time in 15 out of the 16 AA homozygotes; Selleck Dasatinib whereas only 10 out of 19 C allele carriers observed this degree of improvement. Average RPE, VO2, RER and heart rate for the 40-km time trial are shown in Table 2. There was a main effect for Treatment for both VO2 and HR, with both variables higher in the caffeinated condition versus placebo (p < 0.001). Furthermore, there was a main effect of Genotype for VO2, with C allele carriers exhibiting significantly higher average VO2 than AA homozygotes (p = 0.03). There were no significant main effects or interaction effects for RPE or RER. Figure 1 Average (mean ± SE) 40 kilometer time for the caffeine and placebo treatments for both groups. *-Significantly (p < 0.05) larger decrease in 40 K time than the C allele carriers. Figure 2 40-km time in both the placebo condition (y-axis) and the caffeinated condition (x-axis) for both AA Carbohydrate homozygotes and C allele carriers. The line of identity is plotted and reflects no difference between the two trials. Data points above the line of identity reflect an improved 40-km time in the caffeinated condition. Table 2 Average (mean ± SD) values during the 40 k trial for Ratings of Perceived Exertion, VO2, Respiratory Exchange Ratio, and Heart Rate RPE Genotype Caffeine Placebo AA 14.3 ± 1.6 14.2 ± 1.6 C 15.0 ± 1.4 14.9 ± 1.4 VO2 (L·min-1)ab AA 3.08 ± 0.41 2.88 ± 0.49 C 3.43 ± 0.48 3.23 ± 0.48 RER AA 0.92 ± 0.05 0.91 ± 0.04 C 0.94 ± 0.05 0.94 ± 0.